



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Stephen T. Wellinghoff, et al.

SERIAL NO.: 10/056,121

FILED: January 23, 2002

TITLE: Novel Mesogens

§
§
§
§
§
§
§

Group Art Unit: 1623

Examiner: Not Yet Assigned

Atty Docket: SwRI-2385-Z

GP/1623
RECEIVED
APR 25 2002
TECH CENTER 1600/2900

#3

Commissioner of Patents and Trademarks
Washington, D.C. 20231

BEST AVAILABLE COPY

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the references listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

This Information Disclosure Statement is not to be considered as a representation that a search has been made or that no other material information as defined under 37 C.F.R. § 1.56 exists.

The commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 50-0997 (SWRI-2835-Z).

Dated:

4-19-2002

Respectfully submitted,

Paula D. Morris

Paula D. Morris
Registration No. 31,516
Paula D. Morris & Associates, PC
2925 Briar Park Drive, Suite 930
Houston, Texas 77042
Telephone: (713) 334-5151
Facsimile: (713) 334-5157

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10

I hereby certify that this paper, along with any referred to as being attached or enclosed, is being forwarded to Commissioner of Patents and Trademarks, Washington, D.C. 20231, via the United States Postal Service, First Class Mail, prepaid on the 19 day of April, 2002.

By:

Ellen Peacock
Ellen Peacock